Capital Research Global Investors’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-670,407
| Closed | -$55.4M | – | 446 |
|
|
2022
Q3 | $55.4M | Buy |
670,407
+245
| +0% | +$23.6K | 0.02% | 310 |
|
|
2022
Q2 | $63.7M | Hold |
670,162
| – | – | 0.02% | 306 |
|
|
2022
Q1 | $78.9M | Sell |
670,162
-818,854
| -55% | -$91.9M | 0.02% | 330 |
|
|
2021
Q4 | $193M | Sell |
1,489,016
-4,909,845
| -77% | -$573M | 0.04% | 252 |
|
|
2021
Q3 | $724M | Buy |
6,398,861
+465,759
| +8% | +$53.2M | 0.17% | 132 |
|
|
2021
Q2 | $614M | Sell |
5,933,102
-2,539,275
| -30% | -$239M | 0.14% | 141 |
|
|
2021
Q1 | $709M | Sell |
8,472,377
-1,786,094
| -17% | -$151M | 0.17% | 130 |
|
|
2020
Q4 | $936M | Sell |
10,258,471
-258,468
| -2% | -$21.4M | 0.24% | 99 |
|
|
2020
Q3 | $839M | Sell |
10,516,939
-491,885
| -4% | -$38.4M | 0.25% | 93 |
|
|
2020
Q2 | $761M | Sell |
11,008,824
-1,146,642
| -9% | -$81.5M | 0.24% | 94 |
|
|
2020
Q1 | $764M | Sell |
12,155,466
-1,862,781
| -13% | -$134M | 0.3% | 78 |
|
|
2019
Q4 | $1.09B | Buy |
14,018,247
+457,131
| +3% | +$35.7M | 0.33% | 77 |
|
|
2019
Q3 | $994M | Sell |
13,561,116
-1,785,687
| -12% | -$125M | 0.33% | 75 |
|
|
2019
Q2 | $945M | Buy |
15,346,803
+4,568,832
| +42% | +$276M | 0.3% | 78 |
|
|
2019
Q1 | $687M | Sell |
10,777,971
-643,947
| -6% | -$36.7M | 0.22% | 101 |
|
|
2018
Q4 | $583M | Buy |
11,421,918
+786,120
| +7% | +$39.8M | 0.2% | 104 |
|
|
2018
Q3 | $617M | Buy |
10,635,798
+6,619,617
| +165% | +$324M | 0.18% | 117 |
|
|
2018
Q2 | $195M | Buy |
+4,016,181
| New | +$187M | 0.05% | 239 |
|
|
2017
Q4 | – | Sell |
-1,201,158
| Closed | -$43.8M | – | 433 |
|
|
2017
Q3 | $43.8M | Sell |
1,201,158
-3
| -0% | -$114 | 0.01% | 343 |
|
|
2017
Q2 | $47.3M | Sell |
1,201,161
-748,845
| -38% | -$27.3M | 0.01% | 343 |
|
|
2017
Q1 | $61.1M | Sell |
1,950,006
-11,059,908
| -85% | -$346M | 0.02% | 321 |
|
|
2016
Q4 | $406M | Sell |
13,009,914
-6,271,128
| -33% | -$203M | 0.13% | 158 |
|
|
2016
Q3 | $775M | Sell |
19,281,042
-660,000
| -3% | -$24.9M | 0.26% | 104 |
|
|
2016
Q2 | $663M | Sell |
19,941,042
-2,590,758
| -11% | -$88.6M | 0.23% | 118 |
|
|
2016
Q1 | $663M | Sell |
22,531,800
-3,153,000
| -12% | -$87M | 0.23% | 114 |
|
|
2015
Q4 | $676M | Buy |
25,684,800
+748,800
| +3% | +$19.4M | 0.23% | 109 |
|
|
2015
Q3 | $591M | Sell |
24,936,000
-1,272,000
| -5% | -$30.7M | 0.21% | 115 |
|
|
2015
Q2 | $622M | Sell |
26,208,000
-21,628,200
| -45% | -$488M | 0.2% | 114 |
|
|
2015
Q1 | $1.14B | Sell |
47,836,200
-5,044,200
| -10% | -$113M | 0.39% | 70 |
|
|
2014
Q4 | $1.12B | Sell |
52,880,400
-11,548,200
| -18% | -$232M | 0.38% | 71 |
|
|
2014
Q3 | $1.1B | Sell |
64,428,600
-150,000
| -0.2% | -$2.37M | 0.38% | 68 |
|
|
2014
Q2 | $924M | Sell |
64,578,600
-14,988,000
| -19% | -$203M | 0.32% | 83 |
|
|
2014
Q1 | $984M | Sell |
79,566,600
-2,865,000
| -3% | -$33.1M | 0.36% | 81 |
|
|
2013
Q4 | $903M | Sell |
82,431,600
-88,200
| -0.1% | -$994K | 0.33% | 88 |
|
|
2013
Q3 | $958M | Buy |
82,519,800
+477,000
| +0.6% | +$5.58M | 0.38% | 74 |
|
|
2013
Q2 | $919M | Buy |
+82,042,800
| New | +$971M | 0.39% | 72 |
|
Other funds holding EW
Capital Research Global Investors's EW Position: Q4 2022 in Review
Capital Research Global Investors sold out of Edwards Lifesciences (EW) in Q4 2022, closing a stake of 670,407 shares — an estimated $55.4M sold.
Capital Research Global Investors first reported a position in EW in Q2 2013 and held it in 36 quarters. The position peaked at $1.14B in Q1 2015. 1,229 funds tracked by Wall St. Rank hold EW as of Q4 2022.
- Capital Research Global Investors reported no remaining Edwards Lifesciences position as of Q4 2022 after selling out during the quarter.
- Capital Research Global Investors sold 670,407 Edwards Lifesciences shares in Q4 2022, an estimated $55.4M.
- Capital Research Global Investors first reported a position in Edwards Lifesciences in Q2 2013 and held it in 36 quarters.
- Capital Research Global Investors's Edwards Lifesciences position peaked at $1.14B in Q1 2015.
- 1,229 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2022.
Based on Capital Research Global Investors's 13F filing for Q4 2022, filed 14 Feb 2023.